BioMimetic Soars on Trial Results
Positive data from bone graft test gets Franklin company closer to crucial FDA approval
BioMimetic Therapeutics released top-line clinical trial results for its bone graft product late Tuesday that indicate the product performs as well as, and in some cases better than, the current standard of care.
BioMimetic’s Augment Bone Graft is a fully synthetic product designed to promote bone healing. The randomized controlled trial, which looked at hindfoot and ankle fusion surgery, was designed to show that Augment is as effective as autograft – the standard of care procedure that requires surgeons to harvest healthy bone from the patient and transplant it to the surgery site.
Read the full article in the Nashville Post.
